🇺🇸 SECLakefront Biotherapeutics NVQwen · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:44:17·⟳ 抓取 04:44:34 +17s·⚡ 决策 09-09 06:15:01 +1h30m·48.5 天前
Lakefront Biotherapeutics（LKFT.US / Euronext: LKFT）披露8月31日至9月4日按既有回购计划回购132,014股自有股份，合计约328万欧元
跨源已处理消息检查72小时内0条候选，说明本轮不是重复推送；但事件本身只是2026年6月9日已公告回购计划的周度执行明细（数量、均价、总额、库存股余额），属于资本配置doctrine中明确的『进展报告不重复计算首次催化』。相对约18.09亿美元市值，单周328万欧元≈0.2%，不改变每股价值、控制权、流动性或任何盈利/管线预期；6-K封面只是把新闻稿并入既有S-8注册声明的行政引用。方向上既非新增利好也非利空，无可交易edge，故AVOID。
📄 原文Lakefront Biotherapeutics NV↗ 原文
----- f6k_090826.htm ----- 6-K 1 f6k_090826.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 Lakefront Biotherapeutics NV（LKFT.US）
既有回购计划（2026-06-09公告）的例行周度进展披露：本期回购132,014股、均价24.84欧元、总额327.9万欧元，约占18.09亿美元市值的0.2%，库存股1,293,338股且未披露注销；无新增额度、无资金来源或用途变化、无指引与管线信息，6-K封面仅为行政性并入既有S-8。进展报告不重复计算首次催化，方向中性、无edge；且披露于美东盘后（当日已收盘，盘后仅成交1,173股），无当日执行窗口。当日-3.02%的跌幅与本披露无因果关系，既不构成做多催化，也不…
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
一手证据为SEC EDGAR 6-K封面（行政性并入S-8）与Ex-99.1新闻稿全文：Lakefront在2026-08-31至09-04期间通过中介自主委托回购132,014股，均价24.84欧元、总额327.9万欧元，截至09-04持有自有股份1,293,338股。该计划早在2026-06-09已公告，本次仅披露执行明细，无新增额度、无注销/用途变化、无资金来源披露、无管线或指引信息。按行情核验，LKFT.US最新收盘27.63美元（当日-3.02%，5日-3.05%，20日+2.68%），总市值约18.09亿美元，20日日均成交额约750万美元；单周回购金额约占市值0.2%，且回购期股价在28.5→28.5美元区间窄幅波动（24.44–25.38欧元对应），看不出该流量足以构成价格支撑或催化。股价今日下跌3%属与本披露无关的存量波动，且披露于美东盘后（18:12已收盘，盘后仅成交1,173股、无变化），即使有增量也已无当日执行窗口。结论：例行进展报告，无增量事实、无edge，AVOID。
🔎 新鲜度:最早出现 2026-09-08 · 扩散 low · price-in 风险 high ↗
关键理由
- 本次披露只是既有回购计划的执行明细（132,014股/328万欧元），首次方案催化已于2026-06-09释放
- 回购规模约占18.09亿美元市值的0.2%/周，库存股1,293,338股亦未披露注销，难以改变每股价值或供需
- 无任何指引、管线（gamgertamig）、融资或控制权新增信息，6-K封面为行政性并入既有S-8注册声明
主要风险
- 若后续披露回购额度大幅上调、明确注销安排或加速回购，则性质从进展报告转为新催化，需重新研判
- 标的近期股价走弱（当日-3.02%、距60日高点-10.6%、距52周高-26.87%），若与本披露无关的基本面消息出现，会掩盖此类例行披露的读法
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-09-08 · 影响 invalidates
新闻稿明确写明『Within the framework of the repurchase program announced on June 9, 2026』，本期328万欧元、库存股1,293,338股，无注销与加速条款；结合stock_quote市值18.09亿美元，占比约0.2%
检索:回购规模相对市值是否足够大、是否含注销或加速回购条款、是否为新方案 原文 ↗ - 做多前查反向 · 来源 filing · 日期 2026-09-08 · 影响 none
回购期08-31至09-04收盘28.50→28.49美元基本持平（逐日+0.18%/+0.91%/+0.73%/-1.83%），披露日09-08反而-3.02%且发生在盘后披露之前，量比0.6，未见因回购流量形成的正向重定价或抢跑
检索:回购执行期间及披露日股价是否已因该流量重定价、是否存在抢跑 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-09-08 · 影响 none
全文无暂停/缩减回购、无资金或流动性压力表述、无指引与管线负面信息，公司自述资本状况强劲；当日-3.02%属与本事件无关的价格波动，不构成已确认经营损害，故无做空催化、risk_signals为空
检索:是否存在公司级新增净利空（回购暂停、削减、资金缺口、指引下调、管线负面） 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-09-08 · 影响 none
search_processed_events覆盖完整72小时、914条本臂决策，返回0条候选，说明本轮不是重复推送；AVOID依据是无增量事实而非查重命中
检索:72小时内是否已处理过同一回购催化（Lakefront 回购 / LKFT buyback / acquisition of own shares / 6月9日计划）
先例如何影响了这次决策
对本次决策的影响:对最终结论无影响：AVOID由『无增量事实 + 无edge + 美东盘后无执行窗口』决定，先例不会改变标的、方向或订单
方向:未检索：本次为既有回购计划的例行周度进展披露，方向为中性且无新增事实，结论AVOID不依赖历史涨幅分布
涨幅量级:无需幅度校准；即便参考同类回购进展报告，其相对市值0.2%的流量也不足以形成可测的短线定价效应
形态:未做先例面板，不据此推断见光死或高开低走
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 63 ms
{"result": "search_processed_events:agent query=`euronext nasdaq lkft 自有股份回购公告 | lakefront acquisition of own shares repurchase program june 2026 | lakefront biotherapeutics 回购股份 | lkft share repurchase buyback weekly update`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 65.6/72 小时、914 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent - fetch_decision_experience 成功 stock_tools HTTP · 9 ms
{ - stock_quote 成功 stock_tools HTTP · 1,141 ms
{
原文全文
展开原文 · 6,672 字
----- f6k_090826.htm -----
6-K
1
f6k_090826.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On September 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated September 8, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: September 8, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 08 September 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between August 31, 2026 and September 04, 2026 it has repurchased 132,014 Lakefront shares
via a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
31/08/2026
XAMS
24,235
24.73
599,331.55
24.44
24.96
31/08/2026
AQEU
731
24.68
18,038.08
24.60
24.88
31/08/2026
CEUX
3,385
24.67
83,493.39
24.56
24.88
31/08/2026
TQEX
1,779
24.76
44,056.76
24.56
24.88
01/09/2026
XAMS
21,260
24.61
523,180.96
24.46
24.74
01/09/2026
AQEU
380
24.57
9,338.31
24.54
24.70
01/09/2026
CEUX
974
24.56
23,919.39
24.52
24.68
01/09/2026
TQEX
1
24.54
24.54
24.54
24.54
02/09/2026
XAMS
20,515
24.97
512,310.84
24.70
25.38
02/09/2026
AQEU
849
25.03
21,250.89
24.82
25.16
02/09/2026
CEUX
527
24.93
13,136.00
24.82
24.98
02/09/2026
TQEX
138
25.05
3,456.58
24.84
25.16
03/09/2026
XAMS
25,909
25.03
648,592.95
24.86
25.16
03/09/2026
AQEU
192
25.04
4,807.68
25.04
25.04
03/09/2026
CEUX
2,456
25.17
61,819.24
25.04
25.18
04/09/2026
XAMS
24,704
24.85
613,795.58
24.56
25.10
04/09/2026
AQEU
883
24.90
21,989.44
24.76
24.92
04/09/2026
CEUX
3,048
24.85
75,732.74
24.64
25.12
04/09/2026
TQEX
48
24.76
1,188.48
24.76
24.76
Total
132,014
24.84
3,279,463.42
24.44
25.38
As of market close on 04 September 2026, Lakefront holds 1,293,338 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building
a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage
portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell
engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront
identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term
shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1
412 522 6418
sherri.spear@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often,
but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
6-K
1
f6k_090826.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On September 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated September 8, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: September 8, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 08 September 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between August 31, 2026 and September 04, 2026 it has repurchased 132,014 Lakefront shares
via a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
31/08/2026
XAMS
24,235
24.73
599,331.55
24.44
24.96
31/08/2026
AQEU
731
24.68
18,038.08
24.60
24.88
31/08/2026
CEUX
3,385
24.67
83,493.39
24.56
24.88
31/08/2026
TQEX
1,779
24.76
44,056.76
24.56
24.88
01/09/2026
XAMS
21,260
24.61
523,180.96
24.46
24.74
01/09/2026
AQEU
380
24.57
9,338.31
24.54
24.70
01/09/2026
CEUX
974
24.56
23,919.39
24.52
24.68
01/09/2026
TQEX
1
24.54
24.54
24.54
24.54
02/09/2026
XAMS
20,515
24.97
512,310.84
24.70
25.38
02/09/2026
AQEU
849
25.03
21,250.89
24.82
25.16
02/09/2026
CEUX
527
24.93
13,136.00
24.82
24.98
02/09/2026
TQEX
138
25.05
3,456.58
24.84
25.16
03/09/2026
XAMS
25,909
25.03
648,592.95
24.86
25.16
03/09/2026
AQEU
192
25.04
4,807.68
25.04
25.04
03/09/2026
CEUX
2,456
25.17
61,819.24
25.04
25.18
04/09/2026
XAMS
24,704
24.85
613,795.58
24.56
25.10
04/09/2026
AQEU
883
24.90
21,989.44
24.76
24.92
04/09/2026
CEUX
3,048
24.85
75,732.74
24.64
25.12
04/09/2026
TQEX
48
24.76
1,188.48
24.76
24.76
Total
132,014
24.84
3,279,463.42
24.44
25.38
As of market close on 04 September 2026, Lakefront holds 1,293,338 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building
a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage
portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell
engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront
identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term
shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1
412 522 6418
sherri.spear@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often,
but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。